SCHEMBL427188

SCHEMBL427188

O=C(N1CCOCC1)n1ccc(-c2cccnc2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.50
ALDH1A1 P00352 5/20 0.44
HPGD P15428 3/20 0.44
HSD17B10 Q99714 3/20 0.44
KDM4E B2RXH2 2/20 0.44
TP53 P04637 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
PIK3CA P42336 2/20 0.43
PIK3CB P42338 2/20 0.43
PIK3CG P48736 2/20 0.43
MAPT P10636 1/20 0.43
PLAUR Q03405 1/20 0.42
JAK2 O60674 2/20 0.42
TYK2 P29597 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
PIK3CD O00329 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL443092 0.99 HTT (0.49) HTTALDH1A1HPGDHSD17B10KDM4E
SCHEMBL427431 0.87 ALDH1A1 (0.52) HTTALDH1A1HPGDHSD17B10KDM4E
SCHEMBL27843224 0.83 CYP2A6 (0.47) HTTALDH1A1HPGDHSD17B10KDM4E
SCHEMBL25653364 0.72 MKNK1 (0.71) ALDH1A1HPGDPIK3CAMAPT
Nicopholine SCHEMBL29915283 0.69 PKM (0.61) ALDH1A1HPGDTDP1MAPT
Nicopholine SCHEMBL11483977 0.69 PKM (0.61) ALDH1A1HPGDTDP1MAPT
Nicopholine SCHEMBL967933 0.69 PKM (0.61) ALDH1A1HPGDTDP1MAPT
SCHEMBL21634194 0.68 CYP2A6 (0.50) HTTALDH1A1HPGDHSD17B10KDM4E
SCHEMBL427298 0.67 TSHR (0.51) HTTALDH1A1HPGDHSD17B10KDM4E
SCHEMBL424359 0.67 ALDH1A1 (0.51) ALDH1A1HSD17B10TP53CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
WO-2010074588-A2 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 HTT 900/4885ALDH1A1 294/4885HPGD 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.